Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Highly active antiretroviral therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Highly active antiretroviral therapy. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2004-004802-26 Sponsor Protocol Number: SIM-ATOR Start Date*: 2005-03-23
    Sponsor Name:Fundació Lluita contra la SIDA
    Full Title: ESTUDIO DE LA INFLUENCIA DE LAS ESTATINAS EN LA REPLICACIÓN PLASMÁTICA DEL VIH EN PACIENTES CON INFECCION POR EL VIH-1 QUE INTERRUMPEN EL TRATAMIENTO ANTIRRETROVIRAL
    Medical condition: Patients HIV infected
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-001969-16 Sponsor Protocol Number: GS-US-183-0160 Start Date*: 2013-10-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (B...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10020192 HIV-1 LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004060-70 Sponsor Protocol Number: GESIDA-4304 Start Date*: 2005-01-25
    Sponsor Name:Juan Gonzalez García
    Full Title: Pilot study randomised and open to compare the switch to trizivir against the previous treatment in chronic HIV-1 infected patients with liver cirrhosis secondary to Hepatitis C coinfection
    Medical condition: Antiviral treatment of HIV-1 infected patients with liver cirrhosis secondary to Hepatitis C coinfection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-004225-26 Sponsor Protocol Number: GS-US-183-0145 Start Date*: 2008-08-13
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Backgrou...
    Medical condition: Human Innunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10020192 HIV-1 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) PT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002125-30 Sponsor Protocol Number: AELIX-003 Start Date*: 2019-05-09
    Sponsor Name:AELIX Therapeutics
    Full Title: A Phase IIa, randomized, double-blind, placebo-controlled, study of HIV-1 Vaccines MVA.HTI and ChAdOx1.HTI with TLR7 agonist vesatolimod (GS-9620), in early treated HIV-1 infection
    Medical condition: Human immunodeficiency virus type 1
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: View results
    EudraCT Number: 2015-003616-20 Sponsor Protocol Number: MK1439A-030 Start Date*: 2015-12-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects with Selected Non-Nucleoside Reverse Transcriptase Inhi...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10000807 Acute HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003418-32 Sponsor Protocol Number: GS-US-104-0352 Start Date*: 2007-12-18
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase III, Randomised, Open- Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate versus Continuing Stavudine or Zidovudine in Virol...
    Medical condition: HIV-1 infected children (2 years to less than 12 years), who are virologically suppressed with HIV-1 RNA less than 400 copies/mL on their current antiretroviral regimen.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-000590-23 Sponsor Protocol Number: MK-8591A-020 Start Date*: 2020-03-31
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc
    Full Title: A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir Once-Daily in HIV-1 Infected Treatm...
    Medical condition: HIV-1 infection and naïve to antiretroviral therapy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000932-19 Sponsor Protocol Number: SSAT 022 Start Date*: 2008-02-25
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: A phase IV study to assess the feasibility of substituting double ritonavir-boosted protease inhibitors (PI) with ritonavir-boosted darunavir (DRV/r) in HIV-infected individuals with viral suppress...
    Medical condition: HIV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005550-18 Sponsor Protocol Number: 1439A-024 Start Date*: 2015-08-12
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and...
    Medical condition: Human Immunodeficiency Virus-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) DK (Completed) BE (Completed) IT (Completed) ES (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-003988-10 Sponsor Protocol Number: GS-US-380-1490 Start Date*: 2016-02-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infec...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002268-26 Sponsor Protocol Number: CTN240 Start Date*: 2013-01-02
    Sponsor Name:University Health Network, Toronto General Hospital
    Full Title: Valacyclovir in Delaying Antiretroviral Treatment Entry (VALIDATE)
    Medical condition: Coinfection of Human Immunodeficiency Virus and Herpes Simplex Virus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004483-30 Sponsor Protocol Number: GS-US-236-0115 Start Date*: 2012-01-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI/r) plus Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF)...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infections
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) AT (Completed) PT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000587-23 Sponsor Protocol Number: MK-8591A-018 Start Date*: 2020-01-13
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bicte...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Ongoing) FR (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003881-32 Sponsor Protocol Number: 023-01 Start Date*: 2007-09-20
    Sponsor Name:Merck & Co, Inc
    Full Title: Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options.
    Medical condition: HIV-1 infected patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020161 HIV infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) SE (Prematurely Ended) AT (Completed) NL (Completed) LV (Completed) IT (Completed) EE (Completed) SI (Completed) IE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000588-26 Sponsor Protocol Number: MK-8591A-019 Start Date*: 2020-03-02
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc
    Full Title: A Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doraviri...
    Medical condition: HIV-1 infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10068341 HIV-1 infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002045-23 Sponsor Protocol Number: GS-US-180-0104 Start Date*: 2008-07-18
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects.
    Medical condition: Antiretroviral treatment–naive subjects chronically infected with HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002711-15 Sponsor Protocol Number: GS-US-292-1823 Start Date*: 2015-11-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Antiretroviral Agent to the Elvitegr...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002111-41 Sponsor Protocol Number: AI438-047 Start Date*: 2015-05-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug...
    Medical condition: HIV, Adult
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) BE (Completed) NL (Ongoing) GB (Completed) NO (Prematurely Ended) IE (Completed) PT (Completed) GR (Completed) FR (Completed) RO (Trial now transitioned) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001645-14 Sponsor Protocol Number: SYMTRI Start Date*: 2018-08-02
    Sponsor Name:Spanish HIV/AIDS Research Networkº
    Full Title: An open randomized multicenter study comparing TAF/FTC/DRV/cobi vs. ABC/3TC/DTG in HIV-infected antiretroviral naïve patients. (The Symtri study)
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:01:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA